Artificial Intelligence for Regulatory Evidence: A Systematic Document Analysis of European Medicines Agency Regulatory Advice and Public Reports
Clinical Pharmacology & Therapeutics · 2026
DOI: 10.1002/cpt.70300 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2026. Verfasst von Lucina-May Nollen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medicinal Chemistry, LACDR, Leiden University, Leiden, the Netherlands. Hauptthemen laut MEDLINE: Artificial Intelligence. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Artificial intelligence (AI) is receiving increasing attention across the entire lifecycle of medicines, from early development to postauthorization use. While various AI tools have been developed in commercial and academic settings, the extent of their use in regulatory contexts within the European Union remains unknown. In this study, we systematically analyzed the use of AI for regulatory evidence by reviewing Public reports and internal development advice documents from the European Medicines Agency (EMA). Of 26,480 documents screened, 52 documents contained AI use, reflecting 43 unique AI tools used across quality, nonclinical, clinical, and pharmacovigilance domains. The majority of AI tools were deployed in clinical applications, and outputs were used either directly as endpoints, in shaping clinical trial methodology, or in ancillary analyses. Comments and advice from the EMA regarding AI use varied according to the context of use and covered aspects of documentation, methodology, validation, and lifecycle management. Our findings indicate that AI use in regulatory evidence is still limited but showing an increasing trend. As the field is still novel, there are limited regulatory precedents, and AI‐specific guideline development and harmonization across regulatory jurisdictions are still ongoing. In this light, the quantitative characterization of AI tools and AI‐related regulatory comments captured in this analysis provide concrete insights into AI use and frequent regulatory considerations, aiding in both AI tool and AI guideline development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Medicinal Chemistry, LACDR, Leiden University, Leiden, the Netherlands.
- Dutch Medicines Evaluation Board, Utrecht, The Netherlands.
- Swedish Medical Products Agency, Uppsala, Sweden.
- Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
- Division of Pharmacoepidemiology and Clinical Pharmacology Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
ORCID-Profile: Lucina-May Nollen, Gerard J P van Westen, Gabriel Westman, Anna M G Pasmooij
Zitieren
APA
Nollen, L. M., van Westen, G. J. P., Westman, G., & Pasmooij, A. M. G. (2026). Artificial Intelligence for Regulatory Evidence: A Systematic Document Analysis of European Medicines Agency Regulatory Advice and Public Reports. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70300
Vancouver
Nollen LM, van Westen GJP, Westman G, Pasmooij AMG. Artificial Intelligence for Regulatory Evidence: A Systematic Document Analysis of European Medicines Agency Regulatory Advice and Public Reports. Clinical Pharmacology & Therapeutics. 2026. doi:10.1002/cpt.70300
BibTeX
@article{Nollen2026,
author = {Nollen, Lucina-May and van Westen, Gerard J P and Westman, Gabriel and Pasmooij, Anna M G},
title = {Artificial Intelligence for Regulatory Evidence: A Systematic Document Analysis of European Medicines Agency Regulatory Advice and Public Reports},
journal = {Clinical Pharmacology & Therapeutics},
year = {2026},
doi = {10.1002/cpt.70300}
}
EUVIMED